S&P Futures
5,996.50 -7.25 (-0.12%) Dow Futures
43,907.00 -3.00 (-0.01%) Nasdaq Futures
21,160.50 -64.25 (-0.30%) Russell 2000 Futures
2,395.30 -0.40 (-0.02%) Crude Oil
71.54 -0.82 (-1.13%) Gold
2,699.10 -6.70 (-0.25%)
Pharvaris N.V. (9EN.F)
| Previous Close | 20.40 |
| Open | 20.20 |
| Bid | 20.20 x N/A |
| Ask | 21.40 x N/A |
| Day's Range | 20.20 - 20.20 |
| 52 Week Range | 13.60 - 29.60 |
| Volume | |
| Avg. Volume | 2 |
| Market Cap | 1.223B |
| Beta (5Y Monthly) | -3.14 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -2.61 |
| Earnings Date | Aug 14, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 43.14 |
GlobeNewswirePharvaris Presents Clinical and Non-Clinical Data Supporting HAE Development Program at the 2024 ACAAI Annual Scientific Meeting
Data from randomized clinical studies and long-term extension studies support deucrictibant’s potential best-in-class profile, detailing its injectable-like efficacy, placebo-like tolerability, and oral convenienceZUG, Switzerland, Oct. 24, 2024 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to prevent and treat hereditary angioedema (HAE) attacks, today announced data from seven posters that will be
- GlobeNewswire
Pharvaris Announces Data Highlighting Deucrictibant for the Treatment of HAE to be Presented at Upcoming Scientific Meetings
ZUG, Switzerland, Oct. 16, 2024 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to prevent and treat hereditary angioedema (HAE) attacks, today announced the acceptance of multiple abstracts at several upcoming scientific meetings. Presentation details are as follows: American College of Allergy, Asthma, & Immunology’s Annual Scientific Meeting (ACAAI), Boston, October 24-28, 2024. Seven abstracts have
